Aclarion (ACON) announced the first patient enrollment in the Clarity trial evaluating Nociscan’s clinical and economic value in spine surgery. The first patient was enrolled at the Texas Back Institute. The company reaffirms internal interim results of Clarity expected in Q2 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACON:
- Aclarion to present NOCISCAN at State of Spine Surgery Think Tank
- Aclarion adds UHealth, University of Miami as trial site for Nociscan
- Aclarion announces Texas Back Insitute as new CLARITY trial site
- Aclarion announces agreement with the Spine Institute of Louisiana
- Aclarion files $150M mixed securities shelf